IPP Bureau
Jubilant Ingrevia augments its CDMO presence with Rs 270 crore contract
By IPP Bureau - April 17, 2022
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
Evexia Lifecare's Vadodara API facility starts operations
By IPP Bureau - April 17, 2022
The company also plans to expand the facility
Sandoz launches generic brimonidine tartrate eyedrop in US
By IPP Bureau - April 15, 2022
Ocular hypertension affects over 5% of all adults; the eye does not properly drain fluid, causing eye pressure to build up
Lupin receives approval from USFDA for Desvenlafaxine extended-release tablets 25 mg
By IPP Bureau - April 15, 2022
The product will be manufactured at Lupin’s facility in Goa, India
Sinocompound announce new licencing agreement with Dalhousie university
By IPP Bureau - April 15, 2022
The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University
Wockhardt Hospital launch support group for Parkinson patients and families
By IPP Bureau - April 15, 2022
Parkinson’s is not limited to old people, even youngsters can suffer from this disease
Ashland expands distribution deal with Univar for pharma ingredients
By IPP Bureau - April 15, 2022
Under the agreement, Univar Solutions customers in Brazil and Mexico will have access to Ashland's binders and disintegrants for solid dosage forms, matrix formers for modulated release drugs and coatings for regular and modulated release solid dosage forms
Juniper Biologics acquires cell-mediated gene therapy for treatment of knee osteoarthritis
By IPP Bureau - April 13, 2022
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
USFDA grants direct RMAT designation for the use of ExoFlo in Covid-19 related ARDS
By IPP Bureau - April 13, 2022
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies
By IPP Bureau - April 13, 2022
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Shoreline Biosciences showcases novel methodology to produce clinical scale iPSC-derived NK (iNK) cells
By IPP Bureau - April 13, 2022
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
Cloudbyz partners with ClinChoice to provide integrated clinical trial management solutions
By IPP Bureau - April 13, 2022
The joint partnership, powered by Cloudbyz Clinical Research Management Platform and ClinChoice's industry-leading transformation services, will provide an end-to-end clinical research management technology platform and services to customers
Novel Covid-19 vaccine may protect the immunocompromised
By IPP Bureau - April 13, 2022
The peptide-based vaccine induces a t cell-dependent response
WeylChem inaugurates new multi-purpose custom manufacturing plant in France
By IPP Bureau - April 13, 2022
The investment of around €7 million significantly enhances the site’s flexibility and capacity in synthesizing modern, complex and even corrosive molecules
Zydus to supply Sagent's caffeine citrate oral solution from Jarod
By IPP Bureau - April 13, 2022
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
